Fora Capital, LLC Bridge Bio Pharma, Inc. Transaction History

Fora Capital, LLC

$903 Million
Q1 2025

A detailed history of Fora Capital, LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Fora Capital, LLC holds 23,428 shares of BBIO stock, worth $790,460. This represents 0.09% of its overall portfolio holdings.

Number of Shares

23,428

Holding current value

$790,460

% of portfolio

0.09%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$28.12 - $37.59 $658,795 - $880,658	23,428 New	23,428 $809,000
Q4 2023 Feb 14, 2024	BUY	$24.02 - $43.89 $850,668 - $1.55 Million	35,415 New	35,415 $1.43 Million
Q3 2021 Nov 15, 2021	SELL	$46.87 - $64.24 $95,286 - $130,599	-2,033 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$46.47 - $63.93 $13,987 - $19,242	-301 Reduced 12.9%	2,033 $124 Million
Q1 2021 May 17, 2021	SELL	$55.47 - $72.35 $478,484 - $624,091	-8,626 Reduced 78.7%	2,334 $144 Million
Q4 2020 Feb 12, 2021	BUY	$38.38 - $71.11 $276,796 - $512,845	7,212 Added 192.42%	10,960 $779,000
Q3 2020 Nov 13, 2020	BUY	$27.2 - $42.19 $32,558 - $50,501	1,197 Added 46.92%	3,748 $141 Million
Q2 2020 Aug 14, 2020	BUY	$22.22 - $35.69 $56,683 - $91,045	2,551 New	2,551 $83 Million

Others Institutions Holding BBIO

# of Institutions

361

Shares Held

185M

Call Options Held

12.8M

Put Options Held

2.09M

Viking Global Investors LP

22.1M
Shares

$744 Million
2.55% of portfolio
Kohlberg Kravis Roberts & Co. L.P. New York, NY

19.3M
Shares

$650 Million
30.7% of portfolio
Vanguard Group Inc Valley Forge, PA

14.9M
Shares

$503 Million
0.01% of portfolio
Black Rock Inc. New York, NY

12.4M
Shares

$420 Million
0.01% of portfolio
Janus Henderson Group PLC London, X0

7.17M
Shares

$242 Million
0.14% of portfolio

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $5B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fora Capital, LLC with notifications on news.

Account